Moleculin Biotech, Inc. (NASDAQ:MBRX) Short Interest Update

Moleculin Biotech, Inc. (NASDAQ:MBRX) saw a significant decrease in short interest in the month of August. As of August 14th, there was short interest totaling 316,392 shares, a decrease of 79.9% from the July 30th total of 1,577,365 shares. Currently, 1.6% of the shares of the stock are short sold. Based on an average trading volume of 2,216,181 shares, the short-interest ratio is currently 0.1 days.

Wall Street Analyst Weigh In

MBRX has been the subject of several research analyst reports. Weiss Ratings restated a “sell (e+)” rating on shares of Moleculin Biotech in a research report on Friday, July 17th. Wall Street Zen upgraded Moleculin Biotech from a “strong sell” rating to a “sell” rating in a research note on Saturday, August 15th. Two analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the stock currently has an average rating of “Hold” and an average price target of $22.00.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Moleculin Biotech stock. Jane Street Group LLC acquired a new stake in Moleculin Biotech, Inc. (NASDAQ:MBRX) in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 22,550 shares of the company’s stock, valued at approximately $75,000. Jane Street Group LLC owned 1.11% of Moleculin Biotech at the end of the most recent quarter. Hedge funds and other institutional investors own 15.52% of the company’s stock.

Moleculin Biotech Price Performance

Shares of NASDAQ:MBRX traded down $0.01 during midday trading on Wednesday, hitting $0.60. The company had a trading volume of 381,178 shares, compared to its average volume of 578,195. Moleculin Biotech has a twelve month low of $0.16 and a twelve month high of $15.75. The stock has a market cap of $11.76 million, a price-to-earnings ratio of -0.08 and a beta of 1.83. The business’s 50-day simple moving average is $1.75 and its 200-day simple moving average is $2.30.

Moleculin Biotech (NASDAQ:MBRX) last announced its quarterly earnings data on Thursday, August 13th. The company reported ($1.40) EPS for the quarter, topping analysts’ consensus estimates of ($1.55) by $0.15. As a group, sell-side analysts forecast that Moleculin Biotech will post -3.01 EPS for the current year.

About Moleculin Biotech

Moleculin Biotech, Inc is a clinical-stage pharmaceutical company focused on the development of novel therapies for the treatment of highly resistant tumors and viral infections. The company’s research platform centers on the design and synthesis of drug candidates that target key cellular pathways in cancer cells and viral replication processes. By leveraging a proprietary chemistry approach, Moleculin aims to address diseases that have limited therapeutic options and high unmet medical need.

The company’s pipeline includes multiple product candidates at various stages of development.